Latest
Type 2 Diabetes Mellitus in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
Polatuzumab Vedotin for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Influence of Facility Patient Volume on Mortality in Classical Hodgkin Lymphoma
Low Erythropoietin Levels May Have Limited Diagnostic Value for Polycythemia Vera
Outcomes With Plerixafor Following Autologous Stem Cell Transplantation for Multiple Myeloma
Venous Thromboembolism Outcomes in Patients With Autoimmune Disorders
Severe Postpartum Hemorrhage as Evidence of an Inherited Bleeding Disorder
Myeloproliferative Neoplasm Prophylaxis May Be Associated With Birth Rate, Maternal Outcomes
Outpatient ASCT for Myeloma Found Safe, Effective With Proper Patient Selection
Testosterone Therapy Associated With Increased Risk for Venous Thromboembolism
Induction Therapy and Hematopoietic Stem Cell Transplantation for Mixed-Phenotype Acute Leukemia
Corticosteroid-Induced Psychiatric Disorders Are Common in Young Patients With Acute Lymphoblastic Leukemia, Lymphoma
Featured Content
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
British Society of Hematology Guideline Update for Point-of-Care Testing in Hematology
Researchers reviewed currently available point-of-care technology and provided recommendations for standardizing use of this technology.
Updated Guidance on Managing Bleeding and Surgery on Antiplatelet Therapy
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Resting vs Activated Platelets: Why Knowing the Difference Makes Financial Sense
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
